Deals

bumpy road rough bad path
Biotech

BioAge inks option agreement for Chinese biotech's obesity asset

BioAge and JiKang Therapeutics will work together to bring the APJ agonist nanobody to the beginning of IND-enabling studies.
Darren Incorvaia Jun 3, 2025 2:06pm
Lung model

Transpire licenses PDE4 inhibitor for lung disease

Jun 3, 2025 9:45am
Moon Lake

Merck made $3B offer for MoonLake—and could revive interest: FT

Jun 3, 2025 9:25am
Photo of apples growing on branches with the sun shining in the background

Sanofi pays $15M for another STAT6 degrader from Nurix collab

Jun 2, 2025 9:50am
Close-up of Benjamin Franklins eyes peering through hundred dollar bills

BMS inks $11B biobucks BioNTech deal to join bispecific rush

Jun 2, 2025 8:59am
finance numbers tape money

Regeneron pens $2B pact for Hansoh's potential rival to Zepbound

Jun 2, 2025 8:20am